Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
19.1 AUD | +0.42% | -9.11% | -23.71% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.71% | 1.61B | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.02% | 246B | |
+9.26% | 213B | |
-4.21% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Larry Glass to Retire from the Neuren Pharmaceuticals Limited's Board of Directors on 31 December 2018